Advertisement

Search Results

Advertisement



Your search for Kenneth C. Anderson, MD matches 66 pages

Showing 51 - 66


multiple myeloma

Promising Compounds in Development for Multiple Myeloma

The term “novel agents” has been used for the past decade to describe proteasome inhibitors and immunomodulatory drugs that are now conventionally used for multiple myeloma. However, even newer agents in development will be considered truly novel when they hit the market, as they represent new...

breast cancer
colorectal cancer
lung cancer
prostate cancer
skin cancer
leukemia
lymphoma
multiple myeloma
survivorship

NCCN Clinical Practice Guidelines in Oncology: 2014 Updates

At the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN), held recently in Hollywood, Florida, NCCN Panel members presented updates for several tumor types, briefly summarized here. For a more complete description of all updates, visit www.nccn.org. Breast Cancer Guidelines ...

Recipients of the David A. Karnofsky Memorial Award and Lecture

2014: H.M. (Bob) Pinedo, MD, PhD 2013: Martine J. Piccart, MD, PhD 2012: Kanti R. Rai, MD 2011: Kenneth Anderson, MD 2010: Daniel D. Von Hoff, MD, FACP 2009: Clara D. Bloomfield, MD 2008: V. Craig Jordan, OBE, PhD, DSc 2007: Robert A. Kyle, MD, MACP 2006: Dennis J. Slamon, MD, PhD 2005: Charles L....

International Leader in Multiple Myeloma Was Inspired by an Early Mentor’s Lessons in Wisdom and Compassion

Kenneth C. Anderson, MD, grew up in Auburn, a small historic town in central Massachusetts that was settled by the English in 1714. His desire to become a doctor bloomed early. “My decision to possibly pursue a career in medicine was first inspired by my mother, who was a registered nurse, and by...

Book Excerpt: Family

I've witnessed incredible courage and zest for life among so many patients from so many walks of life—individuals committed to helping others in spite of their own adversity. Forty years ago, when survival for patients with multiple myeloma was a matter of months, I knew that every person I sat...

solid tumors

Oncologists Tell Inspiring Stories of What It’s  Like to Treat Cancer in The Big Casino

Title: The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful StoriesEditors: Stan Winokur, MD, and Vincent CoppolaPublishing Platform: CreateSpacePublication date: May 2014Price: $9.99; Paperback, 160 pages   In May, Stan Winokur, MD, and co-editor Vincent Coppola, published The...

multiple myeloma

Experts Debate the Need for Upfront vs Late Stem Cell Transplant in Multiple Myeloma

With powerful new drugs capable of achieving sustained and deep remissions in multiple myeloma, the role of upfront stem cell transplantation is being questioned by experts, who debated the pros and cons at the National Comprehensive Cancer Network (NCCN) 9th Annual Congress on Hematologic...

hematologic malignancies

The American Society of Hematology Elects New Leadership

The American Society of Hematology (ASH) recently announced the election of four new members to its Executive Committee, the governing body of the organization, for terms beginning after the 2014 ASH Annual Meeting, which will be held December 6–9 in San Francisco. Kenneth C. Anderson, MD, will...

American Association for Cancer Research Inducts 2015 Class of Fellows of the AACR Academy

The American Association for Cancer Research (AACR) has announced 11 new fellows of the AACR Academy. The AACR Academy is an entity that recognizes individuals who have made exceptional contributions to cancer research and/or cancer-related biomedical science. Only individuals whose work has had a...

skin cancer
breast cancer
multiple myeloma
leukemia
colorectal cancer
prostate cancer
pancreatic cancer

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2015 Updates

For 2 decades, the NCCN Guidelines® have been recognized as the standard of cancer care in the United States, combining evidence, experience, and choice, so that multidisciplinary cancer treatment teams—including patients—are empowered to make informed decisions about cancer care,” said Robert W....

leukemia

A Lasting Legacy

When Emil J Freireich, MD, retires from the University of Texas MD Anderson Cancer Center on September 1, he will have spent 50 years at the institution and a total of 60 years in the pursuit of curing childhood leukemia as well as other cancers and in the educational development of young...

Seventeen ASTRO Members Awarded Fellows Designation

The American Society for Radiation Oncology (ASTRO) has selected 17 distinguished members to receive the ASTRO Fellows designation. The 2015 class of Fellows will receive the recognition at the Awards Ceremony at ­ASTRO’s 57th Annual Meeting on Tuesday, October 20 in San Antonio, Texas. ASTRO...

issues in oncology

Alfred Goldberg, PhD, and Paul Richardson, MD, to Present 2015 ASH Ernest Beutler Lecture

The American Society of Hematology (ASH) will honor Alfred Goldberg, PhD, of Harvard Medical School, and Paul Richardson, MD, of Dana-Farber Cancer Institute, with the 2015 Ernest Beutler Lecture and Prize for their significant research advances in the area of proteasome inhibitors and their...

Cancer Researchers and Clinicians Elected as 2015 AAAS Fellows

The American Association for the Advancement of Science (AAAS) Council elected 347 fellows for 2015, in recognition of their contributions to innovation, education, and scientific leadership. The tradition of electing AAAS fellows began in 1874 to recognize members for their scientifically or...

hematologic malignancies

Preclinical Study Looks at RNA Polymerase I Inhibitor in Refractory AML and Multiple Myeloma

A laboratory study of the investigational drug CX-5461, which blocks the inhibition of RNA polymerase I transcription, has found that it prolonged survival in mouse models of highly aggressive acute myeloid leukemia (AML) and multiple myeloma refractory to standard therapy. In addition, the...

leukemia

Tyrosine Kinase Inhibitors May Improve Treatment Outcomes in Children With Philadelphia Chromosome–Like ALL

Using genomic profiling and next-generation sequencing of patients with BCR-ABL1-like B-progenitor acute lymphoblastic leukemia (B-cell ALL) and Philadelphia chromosome–like ALL, researchers recently identified alterations targeting 18 kinase or cytokine receptor genes. They then determined...

Advertisement

Advertisement




Advertisement